Brian Feagan was a gastroenterologist and leader in the design and implementation of large clinical trials focusing on Crohn's disease and ulcerative colitis[1][3][5]. He was born on June 13, 1954 in London, Ontario, Canada, where he received an HBSc in Bacteriology and Immunology in 1977, an MSc in Medical Microbiology in 1979, and an MD in 1983 from the University of Western Ontario[1][7][9]. He completed a residency in internal medicine, gastroenterology at the University of Western Ontario and postgraduate training in epidemiology and biostatistics at McMaster University[1][4][6]. He served as Professor of Medicine at the Schulich School of Medicine & Dentistry and Professor of Epidemiology and Biostatistics at Western University, as well as Gastroenterologist at the London Health Sciences Centre[1][3][5]. He was the principal investigator in more than 140 multicenter randomized controlled trials in the field of inflammatory bowel disease[3][4][6]. He founded Alimentiv Inc. (formerly Robarts Clinical Trials Inc.), where he was CEO from 1997-2016 and later senior scientific director[1][5]. He died on November 23, 2025 in London, Ontario of a myocardial infarction at the age of 71.[1][5]